nach oben

Die Diabetologie

Erschienen in:

30.05.2023 | Insuline | Im Fokus

Diabetes Update 2023

Viel Neues in der Therapie

verfasst von: Univ.-Prof. Dr. med. Werner A. Scherbaum

Erschienen in: Die Diabetologie | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Auszug

Hier sollen einige der wichtigsten neuen Erkenntnisse auf dem Gebiet der Diabetologie wiedergegeben werden, welche beim Diabetes Update 2023 vorgestellt wurden. Bezüglich einer ausführlicheren Beschreibung neuer Studienergebnisse und deren Wertung durch die Referenten sei auf das Manual der Seminarunterlagen verwiesen [1]. Auf die Themen Typ-1-Diabetes, Herz und Lipide, Sport sowie interventionelle Angiologie wird von den entsprechenden Referenten in diesem Heft in separaten Artikeln eingegangen. …

Hamann A, Martin S, Stumvoll M (Hrsg) (2023) Update Diabetologie. Seminarunterlagen Diabetes Update Bd. 2023 – 18. Diabetologie-Update-Seminar, Mainz

Davies MJ et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925–1966CrossRefPubMedPubMedCentral

American Diabetes Association (2023) Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2023. Suppl.1, Bd. 46, S S140–S157

Wang X, Cheng FTF, Lam TYT et al (2022) Stress hyperglycemia is associated with an increased risk of subsequent development of diabetes among bacteriemic and nonbacteriemic patients. Diabetes Care 45:1438–1444CrossRefPubMed

Wang MT, Huang Y‑L, Lai J‑H et al (2022) Association between specificity of sulfonylureas to cardiac mitochondrial KATP channels and the risk of major adverse cardiovascular events in type 2 diabetes. Diabetes Care 45:1276–1287CrossRefPubMed

Kivimäki M, Strandberg T, Pentti J et al (2022) Body-Mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol 10(4):253–263CrossRefPubMedPubMedCentral

Lee BJ, Yim MH (2021) Comparison of anthropometric and body composition indices in the identification of metabolic factors. Sci Rep 11(1):9931CrossRefPubMedPubMedCentral

Delago-Lista X, Alcala-Diaz JF, Torres-Peña JD et al (2022) Long-term secondary prevention of cardiovascular disease with a mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 399:1876–1885CrossRef

Wimberley T, Horsdal HL, Brikell I et al (2022) Temporally ordered asociations between type 2 diabetes and brain disorders—a register-based cohort study. Bmc Psychiatry 22(1):573CrossRefPubMedPubMedCentral

10.

Lake J, Bortolasci CC, Stuart AL et al (2023) Metformin is protective against the development of mood disorders. Pharmacopsychiatry 56(1):25–31CrossRefPubMed

11.

Calkin CV et al (2022) Treating insulin resistance with metformin as a streategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD Study): A randomized, quadruple-masked, placebo-controlled clinical trail. J Clin Psychiatrs 83(2):21m14022. https://doi.org/10.4088/JCP.21m14022CrossRef

12.

Hamal C, Velugoti LSDR, Tabowei G et al (2022) Metformin for the improvement of comorbid depression symptoms in diabetic patients: A systematic review. Cureus 14(8):e28609. https://doi.org/10.7759/cureus.28609CrossRefPubMedPubMedCentral

13.

Hallström S, Svensson A‑M, Pivodic A (2021) Risk factors and incidence over time for lower extremity amputations in people wit type 1 diabetes: an observational cohort study of 46088 patients from the Swedish Diabetes Registry. Diabetologia 64(12):2751–2761CrossRefPubMedPubMedCentral

14.

Boyko EJ, Zelnick LR, Braffett BH et al (2022) Risk of foot ulcer and lower extremity amputation among participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 45(2):357–364CrossRefPubMedPubMedCentral

15.

Frykberg RG, Franks PJ, Edmonds M et al (2020) A multinational, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cyclical topical wound oxygen (TWO2) therapy in the treatment of chronic diabetic foot ulcers. The TWO2 study. Diabetes Care 43(3):616–624CrossRefPubMed

16.

Engels G (2022) Fußchirurgie beim diabetischen Fußulkus (DFS).Das Entitätenkonzept als Orientierungshilfe. Gefäßchirurgie 27:388–400CrossRef

17.

Fioretto P, Pontremoli R (2022) Expanding the therapy options for diabetic kidney disease. Nat Rev Nephrol 18:78–79CrossRefPubMed

18.

Agarval R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease. The FIDELITY pooled analysis. Eur Heart J 43:474–484CrossRef

19.

Bakris GL, Ruilope LM, Anker SD et al (2022) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103(1):196–206CrossRefPubMed

20.

Merino J, Guasch-Ferré M, Li J et al (2022) Polygenic scores, diet quality, and type 2 diabetes risk: An observational study among 35.759madults from 3 US cohorts. PLoS Med 19(4):e1003972CrossRefPubMedPubMedCentral

21.

Debras C, Chazelas E, Sellem L et al (2022) Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 378:e071204

22.

Debras C, Chazelas E, Srour B et al (2022) Artificial sweeteners and cancer risk: results from the prospective NutriNet-Santé population-based cohort study. PLoS Med 19(3):e1003950. https://doi.org/10.1371/journal.pmed.1003950CrossRefPubMedPubMedCentral

23.

Mathiesen ER, Alibegovic AC, Corcoy R et al (2023) Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, controlled, non-inferiority trial. Lancet Diabetes Endocrinol 11(2):86–95CrossRefPubMed

24.

Crowther CA, Samuel D, McCowan LME et al (2022) Lower versus higher glycemic criteria of gestational diabetes. N Engl J Med 387:587–598CrossRefPubMed

25.

Feig DS et al (2022) Determinants of small for gestational age in women with type 2 diabetes in pregnancy: Who should receive metformin? Diabetes Care 45(7):1532–1539CrossRefPubMed

26.

Gu W, Hortik H, Erasmus HP et al (2021) Trends and the course of liver cirrhosis and its complications in Germany. Nationwide population-based study (2005 to 2018). Lancet. https://doi.org/10.1016/j.lanepe.2021.100240CrossRefPubMedPubMedCentral

27.

Ampuero J (2022) General overview about the current management of nonalcoholic fatty liver disease. Clin Drug Investig 42:39–45CrossRefPubMedPubMedCentral

28.

Chan CC, Tse YK, Liu RNS (2022) Fatty pancreas is independently associated with subsequent diabetes mellitus development. A 10-year prospective cohort study. Clin Gastroenterol Hepatol 20(9):2014–2022.e4CrossRefPubMed

29.

Al Mrabeh A, Hollingsworth GK, Shaw JAM et al (2020) 2‑year remission of type 2 diabetes and pancreas morphology: A post-hoc analysis of the DIRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 8(12):939–948CrossRefPubMed

30.

Wensink MJ, Lu YT et al (2022) Preconception antidiabetic drugs in men and birth defects in offspring. A nationwide cohort study. Ann Intern Med 175:665–673CrossRefPubMedPubMedCentral

31.

Biondi B, Cappola AR (2022) Subclinical hypothyroidism in older individuals. Lancet 10(2):120–141

32.

Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: A narrative review. Adv Ther 39:58–74CrossRefPubMed

33.

Cosman F, Kendler D, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: The importance of treatment sequence. Osteoporos Int 33:1243–1256CrossRefPubMedPubMedCentral

Titel: Diabetes Update 2023
Viel Neues in der Therapie
verfasst von: Univ.-Prof. Dr. med. Werner A. Scherbaum
Publikationsdatum: 30.05.2023
Verlag: Springer Medizin
Schlagwörter: Insuline
Insuline
Sulfonylharnstoffe
Typ-2-Diabetes
Erschienen in: Die Diabetologie / Ausgabe 4/2023
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-023-01054-z

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Kardiologie und Lipide

Formel zur Abschätzung der Dosierung bei Neueinstellung auf Insulin

DDG Praxisempfehlungen: Lipidtherapie bei Patientinnen und Patienten mit Diabetes mellitus

DDG Praxisempfehlungen: Diabetes, Sport und Bewegung

DDG Praxisempfehlungen zur Ernährung von Personen mit Typ-1-Diabetes mellitus

Mitteilungen des BDE

Praxisempfehlungen der Deutschen Diabetes Gesellschaft